<code id='584AEA4F24'></code><style id='584AEA4F24'></style>
    • <acronym id='584AEA4F24'></acronym>
      <center id='584AEA4F24'><center id='584AEA4F24'><tfoot id='584AEA4F24'></tfoot></center><abbr id='584AEA4F24'><dir id='584AEA4F24'><tfoot id='584AEA4F24'></tfoot><noframes id='584AEA4F24'>

    • <optgroup id='584AEA4F24'><strike id='584AEA4F24'><sup id='584AEA4F24'></sup></strike><code id='584AEA4F24'></code></optgroup>
        1. <b id='584AEA4F24'><label id='584AEA4F24'><select id='584AEA4F24'><dt id='584AEA4F24'><span id='584AEA4F24'></span></dt></select></label></b><u id='584AEA4F24'></u>
          <i id='584AEA4F24'><strike id='584AEA4F24'><tt id='584AEA4F24'><pre id='584AEA4F24'></pre></tt></strike></i>

          explore

          explore

          author:knowledge    Page View:5393
          Richard Burr
          North Carolina Senator Richard Burr received strong support from the biotech sector. Gerry Broome/AP

          WASHINGTON — A veteran senator and champion of the biotech sector beat back an unusually strong challenge Tuesday night — thanks in large part to loyal support from the industry.

          North Carolina Senator Richard Burr, a Republican who has long protected the bioscience companies that drive his state’s economy, overcame a surprisingly robust challenge from Democratic candidate Deborah K. Ross.

          advertisement

          Burr, now finishing his second term in the Senate, serves on committees with oversight of both the Food and Drug Administration and Medicare and Medicaid. He is also chairman of the Select Committee on Intelligence.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more
          It's time to take a new tack for treating Alzheimer's
          It's time to take a new tack for treating Alzheimer's

          AdobeIfinsanityisdoingthesamethingoverandoveragainbutexpectingdifferentresults,thenthelastdecadeorso

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Listen: BridgeBio's big week & Lilly's Alzheimer's data

          SammyKimballforSTATWhatcanHomerteachusaboutbiotech?HasBigSciencegottentoobig?Andwhat’sthefutureoftre